Orthobiologic products developer Bioventus prices upsized IPO at $13, below the range

Bioventus, which offers orthobiologics products for musculoskeletal conditions, raised $104 million by offering 8 million shares at $13, below the range of $16 to $18. The company offered 0.7 million more shares than anticipated. At pricing, Bioventus commands a market value of $Read More